What Happens When You Stop Taking Ozempic?

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound produce meaningful weight loss while you are taking them. But what happens when you stop?

This is one of the most common questions people have, and the honest answer matters for making long-term decisions about treatment.

Weight regain is expected, and why that is not a failure

The most consistent finding across clinical trials is that most people regain a significant amount of the weight they lost when they stop GLP-1 therapy.

The STEP 1 trial extension is the most cited study on this. Participants took semaglutide 2.4 mg (Wegovy) for 68 weeks, then stopped. Within 52 weeks of stopping:

• Participants regained approximately two thirds of their lost weight
• One year after stopping, body weight was on average about 5.6% below where participants started the trial
• Cardiometabolic benefits (blood pressure, cholesterol, blood sugar) also partially reversed

Similar findings have been reported after stopping tirzepatide: in the SURMOUNT-4 trial, people switched to placebo after 36 weeks on tirzepatide regained an average of 14% of body weight over the next year, while those who continued lost more.

Why does the weight come back?

This is important to understand. The weight returns not because of something wrong with the patient, but because:

Obesity is a chronic condition. GLP-1 medications treat it the same way blood pressure medication treats hypertension, they work while you take them. When you stop, the underlying biology that caused weight gain remains.

Appetite hormones reset. GLP-1 drugs suppress appetite by activating GLP-1 receptors in the brain and gut. When the drug is removed, those signals return to their pre-treatment state. Hunger comes back, often sharply.

The "set point" has not changed. The body defends a weight range it considers normal, and after stopping medication, it often returns toward that range.

Timeline: what to expect week by week

Blood sugar control after stopping (for diabetes patients)

For people taking Ozempic or Mounjaro specifically for type 2 diabetes, stopping the medication typically leads to:

• Rising blood glucose within days to weeks
• A1C rising back toward pre-treatment levels over the following months
• Possible need to restart or switch to another diabetes medication

Do not stop diabetes medication without discussing it with your prescribing doctor first.

Stopping before surgery: what you need to know

GLP-1 medications slow gastric emptying, food stays in the stomach longer than usual. This creates a risk during general anaesthesia or deep sedation: stomach contents can be aspirated into the lungs, which is a serious complication.

Guidance has changed. In 2023 the American Society of Anesthesiologists advised holding weekly GLP-1 injections for a week before surgery. Updated multi-society guidance published in October 2024 (ASA, AGA, ASMBS, ISPCOP and SAGES) says most patients can continue GLP-1 medications before elective surgery. For people at higher risk, such as those still increasing their dose or with ongoing nausea or vomiting, the team may advise a liquid-only diet for 24 hours beforehand, hold the medicine, or delay the procedure. Stopping can also raise blood sugar in people with diabetes.

Local protocols differ between hospitals and countries. Always inform your surgical team that you are on a GLP-1 drug, and follow their specific instructions rather than stopping on your own.

Stopping before pregnancy

For semaglutide (Ozempic, Wegovy, Rybelsus), the labels advise stopping at least two months before a planned pregnancy because the drug stays in the body for a long time. For tirzepatide (Mounjaro, Zepbound), ask your prescriber about timing; tirzepatide can also make oral contraceptive pills less effective, so a non-oral or barrier method is advised for 4 weeks after starting and after each dose increase. There is insufficient safety data for use during pregnancy, and animal studies showed potential developmental risks. If you have diabetes, your doctor will plan another way to control blood sugar. Plan this transition well in advance with your doctor.

Strategies for maintaining weight after stopping

If you stop GLP-1 therapy, a structured maintenance plan helps reduce regain:

1. Maintain protein intake: higher protein improves satiety and preserves muscle
2. Keep a consistent food and activity log: structured tracking slows drift
3. Monitor weekly weight: catching small gains early is easier than reversing large ones
4. Ask about maintenance options: some prescribers discuss a long-term maintenance plan rather than stopping fully; this is a decision for your prescriber, not a dose change to make yourself
5. Address the conditions that drive overeating: sleep, stress, and environment all matter

Is it ever the right decision to stop?

Yes, for many reasons:

• Side effects that do not resolve
• Pregnancy planning
• Cost or access
• Reaching a goal and wanting to trial off-medication maintenance
• Medical instruction before a procedure

The decision should be made with your doctor, not unilaterally.

Tracking through discontinuation

If you are stopping, the weeks immediately after are the most important to track carefully. Appetite changes, weight shifts, and symptom changes all tend to move quickly. Having a clear record of where you were on the drug makes it easier to assess what changes are occurring and when they started.

Weight Easy tracks weight, dose history, and weekly symptom patterns, useful reference data both during treatment and when you come off it.

Final takeaway

Most people regain significant weight after stopping Ozempic or other GLP-1 medications, usually within 12 months. This reflects the chronic nature of obesity rather than any personal failure. Before surgery, tell your surgical team well in advance and follow their protocol; most people can now continue their GLP-1. Before a planned pregnancy, semaglutide should be stopped at least two months ahead. Managing the transition with a plan, protein targets, tracking, and medical support, gives the best chance of maintaining progress.

Consult your healthcare provider before stopping any prescription medication.

Consult your healthcare provider before starting any medication.

Sources

• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• Mounjaro prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s034lbl.pdf
• Zepbound prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf

Related Articles

• Can You Stop Obeda Suddenly?

• GLP-1 Weight Loss Plateau: What to Do

• Long-Term Safety of Semaglutide: What the Evidence Shows

• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553–1564 (STEP 1 extension)

• Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48: https://jamanetwork.com/journals/jama/fullarticle/2812936

• American Society of Anesthesiologists. New multi-society clinical practice guidance on GLP-1 receptor agonists before elective surgery, October 29, 2024: https://asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance

• Zepbound prescribing information (oral contraceptive advice): https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf

• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf

• Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf